BR112019010692A2 - transcrição controlável - Google Patents

transcrição controlável

Info

Publication number
BR112019010692A2
BR112019010692A2 BR112019010692A BR112019010692A BR112019010692A2 BR 112019010692 A2 BR112019010692 A2 BR 112019010692A2 BR 112019010692 A BR112019010692 A BR 112019010692A BR 112019010692 A BR112019010692 A BR 112019010692A BR 112019010692 A2 BR112019010692 A2 BR 112019010692A2
Authority
BR
Brazil
Prior art keywords
transcription
inducible
introducing
stem cells
pluripotent stem
Prior art date
Application number
BR112019010692A
Other languages
English (en)
Inventor
Bertero Alessandro
Ortmann Daniel
Vallier Ludovic
Kotter Mark
Pawlowski Matthias
Original Assignee
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58073446&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019010692(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cambridge Entpr Ltd filed Critical Cambridge Entpr Ltd
Publication of BR112019010692A2 publication Critical patent/BR112019010692A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)

Abstract

a presente invenção se refere a um método estável para introduzir pelo menos um cassete induzível em uma célula, e que permite a transcrição controlável de dentro de tal cassete induzível. o método pode ser usado para qualquer tipo de célula, de qualquer organismo eucariótico, porém, tem uma aplicação particular na introdução de cassetes induzíveis em células-tronco pluripotentes, como células-tronco pluripotentes animais ou humanas (hpscs). o cassete induzível é inserido de dorma controlável, de tal modo que assegure que o material genético que contém não seja silenciado ou submetido a influências negativas do sítio de inserção, e a transcrição do material genético seja controlada.
BR112019010692A 2016-11-24 2017-11-24 transcrição controlável BR112019010692A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1619876.4A GB201619876D0 (en) 2016-11-24 2016-11-24 Controllable transcription
PCT/GB2017/053531 WO2018096343A1 (en) 2016-11-24 2017-11-24 Controllable transcription

Publications (1)

Publication Number Publication Date
BR112019010692A2 true BR112019010692A2 (pt) 2019-10-22

Family

ID=58073446

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019010692A BR112019010692A2 (pt) 2016-11-24 2017-11-24 transcrição controlável

Country Status (22)

Country Link
US (4) US11697823B2 (pt)
EP (3) EP4092110A1 (pt)
JP (2) JP2020501533A (pt)
KR (3) KR102500322B1 (pt)
CN (3) CN110249045B (pt)
AU (2) AU2017363950A1 (pt)
BR (1) BR112019010692A2 (pt)
CA (1) CA3044628A1 (pt)
DK (1) DK3545079T3 (pt)
EA (1) EA201991255A1 (pt)
ES (1) ES2918013T3 (pt)
GB (1) GB201619876D0 (pt)
HR (1) HRP20220836T1 (pt)
HU (1) HUE059163T2 (pt)
IL (1) IL266832A (pt)
LT (1) LT3545079T (pt)
MX (1) MX2019006025A (pt)
PL (1) PL3545079T3 (pt)
PT (1) PT3545079T (pt)
RS (1) RS63330B1 (pt)
SI (1) SI3545079T1 (pt)
WO (1) WO2018096343A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201210857D0 (en) * 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
GB201619876D0 (en) 2016-11-24 2017-01-11 Cambridge Entpr Ltd Controllable transcription
SG11201912235PA (en) 2017-07-31 2020-01-30 Regeneron Pharma Cas-transgenic mouse embryonic stem cells and mice and uses thereof
AU2019226526A1 (en) * 2018-03-02 2020-10-15 Generation Bio Co. Identifying and characterizing genomic safe harbors (GSH) in humans and murine genomes, and viral and non-viral vector compositions for targeted integration at an identified GSH loci
CA3089331A1 (en) 2018-03-19 2019-09-26 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
US20210395690A1 (en) * 2018-11-08 2021-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anchorage-independent cells and use thereof
EP3990636A1 (en) * 2019-06-28 2022-05-04 CRISPR Therapeutics AG Materials and methods for controlling gene editing
CN110592014A (zh) * 2019-08-14 2019-12-20 广东美赛尔细胞生物科技有限公司 一种在nk细胞治疗中免辐照体外体内持续去除饲养细胞的方法
JP2023510916A (ja) * 2020-01-17 2023-03-15 サナ バイオテクノロジー，インコーポレイテッド 遺伝子発現の制御のための安全スイッチ
WO2021181110A1 (en) 2020-03-11 2021-09-16 Bit Bio Limited Method of generating hepatic cells
CN115551994A (zh) 2020-03-11 2022-12-30 倍特博有限公司 产生肝细胞的方法
CN112342196A (zh) * 2020-08-18 2021-02-09 未来智人再生医学研究院(广州)有限公司 一种免疫兼容可逆的通用型多能干细胞及其应用
WO2022054856A1 (ja) * 2020-09-10 2022-03-17 Jsr株式会社 オリゴデンドロサイト様細胞の製造方法
CN112430624B (zh) * 2020-11-25 2023-08-18 汕头大学 一种斑马鱼肌肉特异诱导型表达载体及应用
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN114107211A (zh) * 2020-12-04 2022-03-01 未来智人再生医学研究院(广州)有限公司 一种多能干细胞及其衍生物
JPWO2022118972A1 (pt) * 2020-12-04 2022-06-09
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022163466A1 (ja) * 2021-01-26 2022-08-04 アイ ピース， インコーポレイテッド オリゴデンドロサイトの作製方法
GB202112937D0 (en) 2021-09-10 2021-10-27 Cambridge Entpr Ltd Production of hepatocytes
IL311895A (en) 2021-10-19 2024-06-01 Eat Scifi Inc A hybrid meat substitute based on plants/animal cells
WO2023067090A1 (en) 2021-10-20 2023-04-27 Roslin Technologies Limited Ipsc induction and progeny derivation
WO2023135318A1 (en) * 2022-01-17 2023-07-20 Westfälische Wilhelms-Universität Münster Method for expression of a transgene of interest from neural precursor cells
GB202206113D0 (en) 2022-04-27 2022-06-08 Cambridge Entpr Ltd Novel method
EP4342979A1 (en) 2022-09-20 2024-03-27 Bit Bio Discovery GmbH Novel method

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126418A0 (en) 1996-04-05 1999-05-09 Salk Inst For Biological Studi Hormone-mediated methods for modulating expression of exogenous genes and pharmaceutical compositions for modulating the same
JPH1080274A (ja) * 1996-09-06 1998-03-31 Hirofumi Hamada 核移行シグナルを結合したテトラサイクリン・トランスアクチベーター
EP1888750A1 (en) 2005-06-09 2008-02-20 ARTEMIS Pharmaceuticals GmbH Shrna and sirna expression in a living organism under control op a codon-optimized tetracycline repressor gene
SG10201508995QA (en) 2005-07-26 2015-11-27 Sangamo Biosciences Inc Targeted integration and expression of exogenous nucleic acid sequences
CA2675952A1 (en) 2007-01-19 2008-07-24 Mount Sinai School Of Medicine Of New York University Stem cell gene targeting
GB0905331D0 (en) 2009-03-27 2009-05-13 Avecia Biolog Ltd Expression process
CA2756833C (en) * 2009-04-09 2019-11-19 Sangamo Biosciences, Inc. Targeted integration into stem cells
MX2014009835A (es) 2012-02-15 2014-12-08 Mice With Horns Llc Animales transgénicos con características personalizables.
KR101535070B1 (ko) 2014-07-16 2015-07-10 서울대학교산학협력단 혈관성장인자 유전자의 형질전환을 위한 재조합 발현 벡터 및 이를 이용한 혈관성장인자 발현 줄기세포주
JP2018513686A (ja) 2015-04-10 2018-05-31 シンガポール科学技術研究庁Ａｇｅｎｃｙ ｆｏｒ Ｓｃｉｅｎｃｅ， Ｔｅｃｈｎｏｌｏｇｙ ａｎｄ Ｒｅｓｅａｒｃｈ 幹細胞からの機能性細胞の生成
JP2018515139A (ja) * 2015-05-08 2018-06-14 プレジデント アンド フェローズ オブ ハーバード カレッジ 万能ドナー幹細胞および関連する方法
WO2016210313A1 (en) 2015-06-24 2016-12-29 Whitehead Institute For Biomedical Research Culture medium for generating microglia from pluripotent stem cells and related methods
JP6713691B2 (ja) 2015-08-20 2020-07-01 大学共同利用機関法人情報・システム研究機構 動物細胞ゲノム部位特異的外来ｄｎａ挿入方法及び前記挿入方法を用いて得られる細胞
CA3006618A1 (en) 2015-12-01 2017-06-08 Crispr Therapeutics Ag Materials and methods for treatment of alpha-1 antitrypsin deficiency
BR112018012894A2 (pt) 2015-12-23 2018-12-04 Crispr Therapeutics Ag materiais e métodos para tratamento de esclerose lateral amiotrófica e/ou degeneração lobular frontotemporal
EP3416689B1 (en) 2016-02-18 2023-01-18 CRISPR Therapeutics AG Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
EP3429632B1 (en) 2016-03-16 2023-01-04 CRISPR Therapeutics AG Materials and methods for treatment of hereditary haemochromatosis
GB201619876D0 (en) 2016-11-24 2017-01-11 Cambridge Entpr Ltd Controllable transcription
US20200063105A1 (en) 2017-05-01 2020-02-27 President And Fellows Of Harvard College Transcription factors controlling differentiation of stem cells
CN112852877A (zh) 2021-04-07 2021-05-28 成都中科奥格生物科技有限公司 质粒载体及其在靶向猪col1a1位点定点整合外源基因中的应用

Also Published As

Publication number Publication date
HUE059163T2 (hu) 2022-10-28
RS63330B1 (sr) 2022-07-29
CN110249045A (zh) 2019-09-17
SI3545079T1 (sl) 2022-09-30
MX2019006025A (es) 2019-11-25
CA3044628A1 (en) 2018-05-31
IL266832A (en) 2019-07-31
GB201619876D0 (en) 2017-01-11
AU2024203288A1 (en) 2024-06-06
KR102622856B1 (ko) 2024-01-08
KR102500322B1 (ko) 2023-02-16
US20240200098A1 (en) 2024-06-20
US20190338309A1 (en) 2019-11-07
CN117587067A (zh) 2024-02-23
KR20190084309A (ko) 2019-07-16
PL3545079T3 (pl) 2022-07-25
LT3545079T (lt) 2022-06-10
US11697823B2 (en) 2023-07-11
CN110249045B (zh) 2023-11-24
EP4092110A1 (en) 2022-11-23
EA201991255A1 (ru) 2019-11-29
KR20240007714A (ko) 2024-01-16
EP3545079B1 (en) 2022-04-06
JP2020501533A (ja) 2020-01-23
PT3545079T (pt) 2022-07-07
EP3545079A1 (en) 2019-10-02
US20240002880A1 (en) 2024-01-04
US20230392165A1 (en) 2023-12-07
HRP20220836T1 (hr) 2022-10-14
ES2918013T3 (es) 2022-07-13
EP4186972A1 (en) 2023-05-31
CN117512009A (zh) 2024-02-06
DK3545079T3 (da) 2022-06-13
KR20230025947A (ko) 2023-02-23
JP2023134465A (ja) 2023-09-27
WO2018096343A1 (en) 2018-05-31
AU2017363950A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
BR112019010692A2 (pt) transcrição controlável
BR112017003757A2 (pt) ?plantas de milho, partes de planta de milho ou sementes de milho?
MX2018001617A (es) Composiciones de crispr-cas9 diseñados y metodos de uso.
AR101080A1 (es) Transformación de maíz haploide con una nucleasa específica de sitio
CO2019011450A2 (es) Expresión transgénica selectiva de tejidos
MX2019012311A (es) Metodos y composiciones para modificaciones geneticas dirigidas y metodos de uso.
BR112016029650A2 (pt) roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
SA517390590B1 (ar) Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
UY37565A (es) Agentes de iarn alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y métodos de uso
CL2018000070A1 (es) Modulares de diaciglicerol aciltransderasa 2 (dgta2)
EP3701041A4 (en) METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH DEPLETED T-LYMPHOCYTES
MX2017002900A (es) Terapia genica de globina para el tratamiento de hemoglobinopatias.
MX2016011812A (es) Uso in vivo e in vitro de grafeno.
AR107242A1 (es) Preparación térmica de esporas bacterianas
GB2535666A (en) Antimicrobial compositions
AR086995A1 (es) Metodos y composiciones para producir plantas con esterilidad masculina
BR112017006469A2 (pt) composições e métodos para inibição de expressão do gene hao1 (hidroxiácido oxidase 1 (glicolato oxidase))
GB2562396A (en) Devices for simulating a function of a liver tissue and methods of use and manufacturing thereof
WO2014153115A3 (en) Compositions and methods for reprogramming hematopoietic stem cell lineages
AU2016250905A8 (en) Generation of muscle-lineage cells from stem cells
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX2021014306A (es) Composiciones y métodos para la modificación de cd33.
PH12018502061A1 (en) Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]